Literature DB >> 9158821

Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol.

M N Fahie-Wilson1, S G Soule.   

Abstract

For a period of 12 months all samples submitted for serum prolactin (PRL) assay and with PRL > 700 mU/L were examined by gel filtration chromatography. In 17 (25%) of 69 samples we found macroprolactin. The Delfia and Immuno 1 immunoassay systems gave similar PRL results with samples containing macroprolactin whereas the ACS 180 system gave lower results. With the Delfia and Immuno 1 systems samples containing substantial quantities of macroprolactin showed low recovery of PRL after precipitation with polyethylene glycol 6000 (PEG 6000) and this technique can be used as a screening test for macroprolactinaemia. We conclude that macroprolactinaemia is a common phenomenon and, in assays which detect this species, is a common cause of hyperprolactinaemia. Macroprolactinaemia may contribute to the difficulty in establishing an upper limit of the reference range for serum PRL. In our experience, patients with macroprolactinaemia do not exhibit features of the hyperprolactinaemia syndrome and it is important to recognize macroprolactin as the cause of hyperprolactinaemia to avoid unnecessary investigation and treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9158821     DOI: 10.1177/000456329703400305

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  22 in total

Review 1.  ACP best practice no 170. Investigation of infertility with the emphasis on laboratory testing and with reference to radiological imaging.

Authors:  C Williams; T Giannopoulos; E A Sherriff
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

2.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Authors:  Gonca Tamer; Ayşegül Telci; Meral Mert; Ayse Kubat Uzum; Ferihan Aral; Refik Tanakol; Sema Yarman; Harika Boztepe; Nese Colak; Faruk Alagöl
Journal:  Endocrine       Date:  2011-09-30       Impact factor: 3.633

3.  Establishment of reference interval of serum prolactin in an Indian population.

Authors:  Kapil Deb Lahiri; Mriganka Baruah; Joya Ghosh; Soumendyu Sengupta
Journal:  J Clin Diagn Res       Date:  2014-07-20

4.  Prevalence and reproductive manifestations of macroprolactinemia.

Authors:  Amanpreet Kaur Kalsi; Ashutosh Halder; Manish Jain; P K Chaturvedi; J B Sharma
Journal:  Endocrine       Date:  2018-09-29       Impact factor: 3.633

5.  Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays.

Authors:  B Cavaco; S Prazeres; M A Santos; L G Sobrinho; V Leite
Journal:  J Endocrinol Invest       Date:  1999-03       Impact factor: 4.256

6.  Clinical and radiological findings in macroprolactinemia.

Authors:  Serhat Isik; Dilek Berker; Yasemin Ates Tutuncu; Ufuk Ozuguz; Ferhat Gokay; Gonul Erden; Hatice Nursun Ozcan; Ferit Kerim Kucukler; Yusuf Aydin; Serdar Guler
Journal:  Endocrine       Date:  2011-12-21       Impact factor: 3.633

Review 7.  Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues.

Authors:  Mohamed Saleem; Helen Martin; Penelope Coates
Journal:  Clin Biochem Rev       Date:  2018-02

8.  Identification of IgG-immunocomplex macroprolactin with an immunometric "sandwich" system: technical and clinical considerations.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; A Valentini
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

9.  Macroprolactinemia: predictability on clinical basis and detection by PEG precipitation with two different immunometric methods.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; F Dal Bosco
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

10.  Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.

Authors:  M Guitelman; M E Colombani-Vidal; C C Zylbersztein; L Fiszlejder; M Zeller; O Levalle; H E Scaglia
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.